Private Equity Investments in Public Healthcare Companies

Private equity firms currently hold 221 positions in publicly-traded healthcare companies. The majority of these are pharmaceutical companies, followed by biotechnology companies.

Pharma

Top private equity firms investing in public Pharmaceutical companies

1. Foresite Capital – 34 positions
2. OrbiMed Advisors – 19 positions
3. Aisling Capital – 14 positions
4. TPG – 5 positions
5. Essex Woodlands – 5 positions

Examples: Private Equity Investments in public Pharmaceutical companies

• Foresite Capital invested in SAGE Therapeutics (SAGE). Market Cap = $6.8 billion
• OrbiMed Advisors invested in CTI BioPharma (CTIC). Market Cap = $113 million
• Aisling Capital invested in GTX (GTXI). Market Cap = $276 million
• TPG invested in Collegium Pharmaceutical (COLL). Market Cap = $579 million
• Essex Woodlands invested in Revance Therapeutics (RVNC). Market Cap = $1.1 billion

BioTech

Top private equity firms investing in public Biotechnology companies

1. Foresite Capital – 17 positions
2. OrbiMed Advisors – 6 positions
3. Polaris Partners – 5 positions
4. Aisling Capital – 4 positions
5. HBM Healthcare Investments – 2 positions

Examples: Private Equity Investments in public Biotechnology companies

• Foresite Capital invested in Jounce Therapeutics (JNCE). Market Cap = $471 million
• OrbiMed Advisors invested in Xtant Medical (XTNT). Market Cap = $10.7 million
• Polaris Partners invested in Editas Medicine (EDIT). Market Cap = $994 million
• Aisling Capital invested in Audentes Therapeutics (BOLD). Market Cap = $852 million
• HBM Healthcare Investments invested in Neurocrine Biosciences (NBIX). Market Cap = $6.2 billion

Related: Read our broader study of Private Equity Investments in Public Companies.